CIK 0001725160
- Non-accelerated filer
- Smaller reporting company
Zentalis Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ZNTL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 823607803
- Phone
- +1 858-263-4333
- Business address
- 10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- Zentalis Pharmaceuticals, LLC, Zeno Pharma, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 24 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-02-14 | Pinto Alexis Chief Legal Officer | Sale | −614 | $50.16 | $31K | 22,317 |
| 2022-02-14 | Pinto Alexis Chief Legal Officer | Sale | −77 | $50.75 | $4K | 22,240 |
| 2022-02-14 | Gallagher Cam Director | Sale | −2,079 | $50.16 | $104K | 400,922 |
| 2022-02-14 | Gallagher Cam Director | Sale | −259 | $50.75 | $13K | 400,663 |
| 2022-02-14 | Gallagher Cam Director | Sale | −4,850 | $50.17 | $243K | 395,813 |
| 2022-02-14 | SUN ANTHONY Y President & CEO | Sale | −4,208 | $50.16 | $211K | 1,217,998 |
| 2022-02-14 | SUN ANTHONY Y President & CEO | Sale | −525 | $50.75 | $27K | 1,217,473 |
| 2022-02-10 | Bunker Kevin D. Chief Operating Officer | Grant or award | +22,481 | 768,798 | ||
| 2022-02-10 | Bunker Kevin D. Chief Operating Officer | Sale | −2,366 | $52.15 | $123K | 177,634 |
| 2022-02-10 | Bunker Kevin D. Chief Operating Officer | Sale | −3,074 | $53.19 | $164K | 174,560 |
| 2022-02-10 | Bunker Kevin D. Chief Operating Officer | Sale | −3,321 | $54.20 | $180K | 171,239 |
| 2022-02-10 | Bunker Kevin D. Chief Operating Officer | Sale | −1,239 | $54.96 | $68K | 170,000 |
| 2022-02-10 | Bunker Kevin D. Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +52,745 | 52,745 | ||
| 2022-02-10 | Voliotis Dimitris SVP, Clinical Development | Grant or award | +10,329 | 16,579 | ||
| 2022-02-10 | Voliotis Dimitris SVP, Clinical Development | Grant or award · Stock Option (Right to Buy) | +24,234 | 24,234 | ||
| 2022-02-10 | Pinto Alexis Chief Legal Officer | Grant or award | +16,405 | 22,931 | ||
| 2022-02-10 | Pinto Alexis Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +38,489 | 38,489 | ||
| 2022-02-10 | Epperly Melissa B, Chief Financial Officer | Grant or award | +16,405 | 266,407 | ||
| 2022-02-10 | Epperly Melissa B, Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +38,489 | 38,489 | ||
| 2022-02-10 | Gallagher Cam Director | Grant or award | +8,203 | 395,406 |
Page 11 of 28 · 545 trades